Sedges adapted to shady habitats, especially species of tropical forests and the deciduous forests of eastern North America and eastern Asia, may have expanded (broad) blades; this includes a number of species of Carex in temperate forests and species of Hypolytrum, Mapania, and Scleria in tropical woodlands.
Furthermore, the ability of MDDCs pulsed with either infectious or AT-2 HIV-1 to activate and expand CD4+ and CD8+ HIV-specific T cells from chronic HIV-infected individuals was examined and DCs pulsed with either form of virus expanded broad HIV-1 specific memory T cell responses targeting major HIV antigens gag, pol, env, and nef (Figure 1C and Larsson et al[25]).
Tigecycline is an expanded broad-spectrum antibiotic representing a new class called "glycylcyclines".
Tigecycline is an intravenous expanded broad-spectrum glycylcycline with in vitro activity against pathogens associated with cSSSI [ 6, 7].
Tigecycline is a novel, first-in-class, glycylcycline antibiotic with expanded broad-spectrum wide in vitro activity against the microorganisms commonly encountered in intra-abdominal infections.
The efficacy and safety of tigecycline, an expanded broad-spectrum glycylcycline antibiotic, was compared with imipenem/cilastatin (IMI/CIS) in patients with cIAI.
Tigecycline, an expanded broad-spectrum glycylcycline, exhibits in vitro activity against many common pathogens associated with community-acquired pneumonia (CAP), as well as penetration into lung tissues that suggests effectiveness in hospitalized CAP patients.
Tigecycline, a first-in-class expanded broad-spectrum glycylcycline antibiotic approved for use in patients with cIAIs, overcomes the 2 major mechanisms of resistance to tetracycline (i.e., drug-specific efflux pump acquisition and ribosomal protection) [ 7, 8].
Tigecycline, a first-in-class, expanded broad-spectrum glycylcycline, demonstrates in vitro activity against many commonly encountered respiratory bacteria, including multiple resistant gram-positive, gram-negative, anaerobic, and "atypical" bacteria such as multidrug-resistant S. pneumoniae and beta-lactamase producing H. influenzae [ 15].
Tigecycline is a first-in-class expanded broad-spectrum, glycylcycline antibiotic [ 19], and is approved by the U.S. FDA for the treatment of community-acquired bacterial pneumonia caused by penicillin-susceptible Streptococcus pneumoniae, beta-lactamase negative Haemophilus influenzae, and Legionella pneumophila.
Leveraging its unique relationship with providers through the CoC accreditation program, the data base will continue to establish itself as the primary source for developing and implementing quality metrics for cancer care improvement, and to retain and expand broad support within the clinical community.
